Keyword: InFLAMES Flagship

How can a researcher become an entrepreneur, what does the journey require and why should more researchers aim to commercialise their invention? The Corporate Corner event of the InFLAMES Flagship shares stories of how science can become business, told by interesting speakers and companies. The theme for the next Corporate Corner is The Journey of Turning Science into Business, and it will be held on 6 October in Turku.

Frontiers of Science Seminar program is ready for autumn 2023. All seminars are on-site only at 12:00 in BioCity, Presidentti auditorium. Coffee and sandwich is served before each seminar.

Human immune cells are capable of coordinating their own movement more independently than previously thought. InFLAMES researcher Jonna Alanko has discovered that immune cells do not just passively follow the chemical cues in their environment. Quite the contrary, they can also shape these cues and navigate in complex environments in a self-organised manner.

This year, the Elias Tillandz Prize was awarded to two outstanding research articles, which involved a mechanism related to the migration of cancer cells and a new analysis of a grave dating back to the early Middle Ages. The Prize was awarded to the researchers at the BioCity symposium on Thursday, 24 August 2023.

Registration to BioCity Symposium is open until 11 August 2023. BioCity Symposium is one of the most important meetings in Turku region for researchers working in the fields of bio- and molecular medicine. This year the event is arranged with title Sculpting tissues – Cells, matrix and forces.

Researchers have found a possible explanation as to why higher breast density and older age increase the risk of breast cancer.

Folate-based radiopharmaceuticals can be used in positron emission tomography (PET) imaging to detect folate receptors in brain tumours. The discovery of folate receptors and their exploitation potential with respect to brain tumours is a new and significant finding in the field.

Docent Pekka Postila and Professor Olli Pentikäinen from the Institute of Biomedicine and InFLAMES Flagship have received 100,000 dollars in funding from the SynGAP Research Fund (SRF) for SynGAP syndrome research.

Through immunotherapies utilising Immune Checkpoint Blockers (ICB), advanced solid cancers can today be treated with unprecedented efficacy. However, not all patients respond positively to these treatments. InFLAMES researcher, Docent Carlos Rogerio Figueiredo and his team are working to uncover the underlying causes of this resistance to ICB. They focus on patients suffering from malignant melanomas and lung cancers as main research models.